2-ethyl-cyclohexanone oxime | 86823-11-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-ethyl-cyclohexanone oxime
• 英文别名: 2-Aethyl-cyclohexanon-oxim；2-Ethyl-1-(hydroxyimino)cyclohexane；N-(2-ethylcyclohexylidene)hydroxylamine
• CAS: 86823-11-2
• 化学式: C₈H₁₅NO
• 分子量: 141.213
• InChiKey: HTRMWUORSYXIAP-UHFFFAOYSA-N

物化性质

• 熔点：
  91 °C
• 沸点：
  120 °C(Press: 20 Torr)
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  32.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-ethyl-cyclohexanone oxime 在 sodium 作用下， 以 乙醇 为溶剂， 以75%的产率得到cis-2-ethylcyclohexylamine
  参考文献：
  名称：

  Stereoselective reductions of substituted cyclohexyl and cyclopentyl carbon-nitrogen .pi. systems with hydride reagents

  摘要：

  DOI：

  10.1021/jo00168a009
• 作为产物：
  描述：

  2-乙基环己酮 在 盐酸羟胺 、 sodium acetate 作用下， 以 乙醇 、 水 为溶剂， 以89%的产率得到2-ethyl-cyclohexanone oxime
  参考文献：
  名称：

  Stereoselective reductions of substituted cyclohexyl and cyclopentyl carbon-nitrogen .pi. systems with hydride reagents

  摘要：

  DOI：

  10.1021/jo00168a009

文献信息

• Novel guanidinobenzamides
  申请人：Chiron Corporation

  公开号：US20030199499A1

  公开（公告）日：2003-10-23

  Compounds of formula IIA and IIB are novel guanidine compounds 1 where the variables R 1 through R 10 have the values set forth herein. Such compounds have use in treating diseases such as obesity and type II diabetes, and may be provided as pharmaceutical formulations in conjunction with a pharmaceutically acceptable carrier.

  化学式为IIA和IIB的化合物是新型的胍类化合物，其中变量R1到R10的取值如下所述。这些化合物在治疗肥胖症和2型糖尿病等疾病方面具有用途，并可与药物可接受载体一起提供作为药物配方。
• Guanidinobenzamides
  申请人：Chiron Corporation

  公开号：US06638927B2

  公开（公告）日：2003-10-28

  Compounds of formula IA and IB are new where the variables R1 through R10 have the values set forth herein. Such compounds have use in treating diseases such as obesity and type II diabetes, and may be provided as pharmaceutical formulations in conjunction with a pharmaceutically acceptable carrier.

  具有公式IA和IB的化合物是新的，其中变量R1到R10具有此处所列的值。这样的化合物在治疗肥胖症和2型糖尿病等疾病方面有用，并且可以与药用载体一起提供作为药物制剂。
• 72. Synthetical and stereochemical investigations of reduced cyclic bases. Part I. Hydrogenation products of indole and the exhaustive methylation of an N-methyloctahydroindole
  作者：F. E. King、J. A. Barltrop、R. J. Walley

  DOI：10.1039/jr9450000277

  日期：——
• 2-Iminohomopiperidinium Salts as Selective Inhibitors of Inducible Nitric Oxide Synthase (iNOS)
  作者：Donald W. Hansen,、Karen B. Peterson、Mahima Trivedi、Steven W. Kramer、Ronald K. Webber、Foe S. Tjoeng、William M. Moore、Gina M. Jerome、Christine M. Kornmeier、Pamela T. Manning、Jane R. Connor、Thomas P. Misko、Mark G. Currie、Barnett S. Pitzele

  DOI：10.1021/jm9704715

  日期：1998.4.1

  An attractive approach to the treatment of inflammatory conditions such as osteo-and rheumatoid arthritis, inflammatory bowel disease, and sepsis is through the selective inhibition of human inducible nitric oxide synthase (hiNOS) since localized excess nitric oxide (NO) release has been implicated in the pathology of these diseases. A series of monosubstituted iminohomopiperidinium salts possessing lipophilic functionality at ring positions 3, 5, 6, and 7 has been synthesized, and series members have demonstrated the ability to inhibit the hiNOS isoform with an IC50 as low as 160 nM (7). Compounds were found that selectively inhibit hiNOS over the human endothelial constitutive enzyme (heNOS) with a heNOS/hiNOS IC50 ratio in excess of 100 and as high as 314 (9). Potencies for inhibition of hiNOS and the human neuronal constitutive enzyme (hnNOS) are comparable. Substitution in the 3 and 7 positions provides compounds that exhibit the greatest degree of selectivity for hiNOS and hnNOS over heNOS. Submicromolar potencies for 6 and 7 in a mouse RAW cell assay demonstrated the ability of these compounds to inhibit iNOS in a cellular environment. These latter compounds were also found to be orally bioavailable and efficacious due to their ability to inhibit the increase in plasma nitrite/nitrate levels in a rat LPS model.